132 related articles for article (PubMed ID: 19485300)
1. Progression of macular ischemia following intravitreal bevacizumab.
Sabet-Peyman EJ; Heussen FM; Thorne JE; Casparis H; Patel SJ; Do DV
Ophthalmic Surg Lasers Imaging; 2009; 40(3):316-8. PubMed ID: 19485300
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis.
Erdurman FC; Durukan AH; Mumcuoğlu T; Hürmeriç V
Ocul Immunol Inflamm; 2009; 17(1):56-8. PubMed ID: 19294575
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
4. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.
Chung EJ; Roh MI; Kwon OW; Koh HJ
Retina; 2008; 28(7):957-63. PubMed ID: 18698297
[TBL] [Abstract][Full Text] [Related]
5. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.
Kumar A; Sinha S
Can J Ophthalmol; 2007 Apr; 42(2):335-6. PubMed ID: 17392871
[No Abstract] [Full Text] [Related]
6. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
Querques G
Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
[No Abstract] [Full Text] [Related]
7. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1.
Michaelides M; Fraser-Bell S; Hamilton R; Kaines A; Egan C; Bunce C; Peto T; Hykin P
Retina; 2010 May; 30(5):781-6. PubMed ID: 20464787
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
Saito W; Kase S; Ohgami K; Mori S; Ohno S
Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
Parveen S; Narayanan R; Sambhav K; Bhatia K
Retina; 2010 Sep; 30(8):1324-5; author reply 1325. PubMed ID: 20827152
[No Abstract] [Full Text] [Related]
10. An unusual optic disc neovascularization in a case of intermediate uveitis associated with multiple sclerosis.
Karagiannis DA; Ladas ID
Eur J Ophthalmol; 2008; 18(6):1020-2. PubMed ID: 18988181
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis.
Akesbi J; Brousseaud FX; Adam R; Rodallec T; Nordmann JP
Acta Ophthalmol; 2010 Mar; 88(2):e40-1. PubMed ID: 19508455
[No Abstract] [Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome.
Amselem L; Montero J; Diaz-Llopis M; Pulido JS; Bakri SJ; Palomares P; Garcia-Delpech S
Am J Ophthalmol; 2007 Jul; 144(1):122-4. PubMed ID: 17601432
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
15. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Isaacs TW; Barry C
Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
[TBL] [Abstract][Full Text] [Related]
16. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study.
Patwardhan SD; Azad R; Shah BM; Sharma Y
Retina; 2011 May; 31(5):866-70. PubMed ID: 21301382
[TBL] [Abstract][Full Text] [Related]
17. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
[TBL] [Abstract][Full Text] [Related]
19. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal injection of bevacizumab in Eales disease.
Küçükerdönmez C; Akova YA; Yilmaz G
Ocul Immunol Inflamm; 2008; 16(1):63-5. PubMed ID: 18379947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
